Beyond Natural Antibodies: Scaffold-Based Generation of Novel Anti-3CLproNanobody Nb01
preprint
OA: closed
Abstract
In the post-pandemic era, continuous mutations and persistent infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pose a significant threat to global health, making the normalization of preventive measures imperative. Due to its high conservation, the 3CLpro is relatively stable across all these variants without significant changes, suggesting that drugs targeting this enzyme could be effective against all variant viruses. And compared to traditional antibodies, nanobodies show significant advantages against SARS-CoV-2 and its variants. Traditional antibodies often lose their inhibitory activity due to viral mutation. Nanobodies are characterised by their small size, high stability, high affinity for antigen binding, and high water solubility, which enable them to capture viruses quickly and effectively address the continuous mutations and persistent infections of SARS-CoV-2. In this research, we devised a strategy to produce nanobodies by utilizing a fragment-generating large language model, resulting in the identification of a nanobody named Nb01. Nb01 exhibits potent and broad-spectrum neutralizing activity against numerous SARS-CoV-2 variants. The nanobody Nb01, directed against the SARS-CoV-2 3CL pro , demonstrated efficacy against the majority of prevalent SARS-CoV-2 variants. Notably, it has a higher affinity than the current best performing nanobodies (S43, bn03, R14, and 3-2A2-4) for most of the variants, including the Alpha (27.5%), Gamma (29.7%), Omicron BA.2 (32.2%), BA.4/5 (81.2%), BF.7 (64.2%) and XBB (5.5%) variants. For other variants, Nb01 displayed affinities that were on par with these benchmark nanobodies. In summary, the exceptional specificity, low toxicity, robust stability, and extensive spectrum of Nb01 indicate its potential to be developed as a nanobody therapeutic for the management of SARS-CoV-2 infections and its diverse variants.
Full text
2,612 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
In the post-pandemic era, continuous mutations and persistent infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pose a significant threat to global health, making the normalization of preventive measures imperative. Due to its high conservation, the 3CLpro is relatively stable across all these variants without significant changes, suggesting that drugs targeting this enzyme could be effective against all variant viruses. And compared to traditional antibodies, nanobodies show significant advantages against SARS-CoV-2 and its variants. Traditional antibodies often lose their inhibitory activity due to viral mutation. Nanobodies are characterised by their small size, high stability, high affinity for antigen binding, and high water solubility, which enable them to capture viruses quickly and effectively address the continuous mutations and persistent infections of SARS-CoV-2. In this research, we devised a strategy to produce nanobodies by utilizing a fragment-generating large language model, resulting in the identification of a nanobody named Nb01. Nb01 exhibits potent and broad-spectrum neutralizing activity against numerous SARS-CoV-2 variants.
The nanobody Nb01, directed against the SARS-CoV-2 3CLpro, demonstrated efficacy against the majority of prevalent SARS-CoV-2 variants. Notably, it has a higher affinity than the current best performing nanobodies (S43, bn03, R14, and 3-2A2-4) for most of the variants, including the Alpha (27.5%), Gamma (29.7%), Omicron BA.2 (32.2%), BA.4/5 (81.2%), BF.7 (64.2%) and XBB (5.5%) variants. For other variants, Nb01 displayed affinities that were on par with these benchmark nanobodies. In summary, the exceptional specificity, low toxicity, robust stability, and extensive spectrum of Nb01 indicate its potential to be developed as a nanobody therapeutic for the management of SARS-CoV-2 infections and its diverse variants.
Competing Interest Statement
This research work was financially supported by Shenzhen Second People's Hospital COVID-19 Emergency Clinical Research Project(2023xgyj3357009) and Shenzhen Science and Technology Program(20231127194506001), Shenzhen Science and Technology Innovation Committee Funds (JSGG20220919091404008), Shenzhen Technology University Innovation and Entrepreneurship Project (S202414655005) and the National Natural Science Foundation of China (81804154).
Footnotes
zhijie.zhan{at}qq.com, 202201101140{at}stumail.sztu.edu.cn, yini.jiang{at}foxmail.com, yinghuali03{at}163.com, caiyuanzhe{at}sztu.edu.cn
w.chong.luo{at}qq.com
huangfeijuan{at}163.com, liujierenxy{at}126.com
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00